Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells
© Zhu et al.; licensee BioMed Central Ltd. 2013
Received: 17 February 2013
Accepted: 31 May 2013
Published: 1 June 2013
Apigenin (4’,5,7-trihydroxyflavone) was recently shown effective in inhibiting several cancers. The aim of this study was to investigate the effect and mechanism of apigenin in the human bladder cancer cell line T24 for the first time.
T24 cells were treated with varying concentrations and time of apigenin. Cell viability was evaluated by MTT assay. Cell motility and invasiveness were assayed by Matrigel migration and invasion assay. Flow cytometry and western blot analysis were used to detect cell apoptosis, cell cycle and signaling pathway.
The results demonstrated that apigenin suppressed proliferation and inhibited the migration and invasion potential of T24 bladder cancer cells in a dose- and time-dependent manner, which was associated with induced G2/M Phase cell cycle arrest and apoptosis. The mechanism of action is like to involve PI3K/Akt pathway and Bcl-2 family proteins. Apigenin increased caspase-3 activity and PARP cleavage, indicating that apigenin induced apoptosis in a caspase-dependent way.
These findings suggest that apigenin may be an effective way for treating human bladder cancer.
Apigenin, one of the most common flavonoids, is widely distributed in many fruits and vegetables, including parsley, onions, orange, tea, chamomile, wheat sprouts and in some seasonings . Apigenin has potential uses in cancer prevention and therapy, and it suppresses cell growth against many human cancer cell lines, including breast, colon, skin, thyroid, leukemia, and prostate cancer cells [2–5]. Unlike other structurally related flavonoids, apigenin is non-mutagenic . Although previous reports have shown the inhibitory effect of apigenin on other human cancer cells, there are few reports indicating the inhibitory effect on human bladder cancer cells.
Bladder cancer is the most common malignant tumor of the urinary tract. Worldwide, bladder cancer is the seventh most common cancer. An average of 386,300 new cases of urinary bladder cancer are diagnosed worldwide every year, accounting for 150,200 deaths . In recent decades, bladder cancer was shown of a rising overall incidence . In most cases of nonmuscle invasive bladder cancer, tumors are treated initially with TURBT (Transurethral Resection of Bladder Tumor). A careful cystoscopic examination of the entire urethra and all bladder surfaces precedes resection. Intravesical therapy can also be employed in an expectant way as opposed to an induction course alone to provide long-term immunostimulation or chemotoxicity and thereby prevent disease recurrence [9, 10]. Our earlier studies have shown that EGCG  and resveratrol  may be an important chemopreventive agent for the management of bladder cancer. Here we proved for the first time that apigenin could induce apoptosis and cell cycle arrest of bladder cells.
Besides many natural agents extracts like EGCG, resveratrol and genistein which are proved of the ability of cancer chemoprevention, apigenin is another agent we often contact. This study was designed to determine whether apigenin decreases the ability of migration and invasion of T24 bladder cells and is apoptotic of T24 bladder cells by inhibiting PI3K/Akt pathway, activating caspases and induces cell cycle arrest. Finally, we showed that in T24 bladder cancer cells apigenin upregulates Bax and Bad, activates caspase-3 and poly (ADPribose) polymerase (PARP), inhibits PI3K/Akt pathway, downregulates antiapoptotic protein Bcl-2 and Bcl-x, and leads to G2/M cell cycle arrest.
Apigenin inhibits cell growth in T24 cells
Apigenin inhibits T24 cell migration and invasion
Apigenin induces apoptosis in T24 cells
Caspase-3 activation and PARP cleavage are characteristic indicators of apoptosis. As a downstream effector in the caspase cascade, when caspase-3 is activated, it induces an irreversible apoptosis . PARP cleavage, procaspase-3 and active caspase-3 protein were detected by western blot. In apigenin-treated T24 cell samples, cleaved PARP and active caspase-3 increased, while procaspase-3 decreased in a dose-dependent manner after 24 h treatment (Figure 3C).
Apigenin induces G2/M phase cell cycle arrest
Apigenin modulates Akt pathway
To further investigate the modulation of apigenin on PI3K-Akt pathway, T24 cells were pretreated with 20 μM PI3 kinase inhibitor LY294002 for 30 min. Cells were than treated with 40 μM apigenin for another 24 h. Cellular proteins were extracted and analyzed by Western blotting. As shown in Figure 5B, PI3K inhibitor, LY294002 decreased the protein levels of cleaved PARP and active casepase-3, suggesting that apigenin-induced apoptosis depended on PI3K-Akt activity.
Apigenin alters Bcl-2 family protein expression in T24 cells
As is known, Bcl-2 family plays a crucial role in apoptosis. The change of the ratio of proapoptotic protein versus antiapoptotic proteins of Bcl-2 family such as Bax and Bcl-2 will activate the mitochondrial apoptotic pathway. In addition, several kinases have been shown to phorylate and inactivate Bad, and Akt is one of them . Therefore we next studied the dose-dependent effects of apigenin on the constitutive protein levels of Bcl-2 family in T24 cells. The Western blot analysis showed a significant increase in the expression of pro-apoptotic protein Bax and Bad, while in sharp contrast, the protein expression of Bcl-2 and Bcl-xl was significantly decreased by apigenin treatment in a dose-dependent manner (Figure 5C). The results revealed evidence that apigenin-induced apoptosis was involved with Bcl-2 family.
In this study, we showed that apigenin, a nonmutagenic antitumor flavonoid, exhibits an inhibition action on T24 bladder cancer cells for the first time. We confirmed the chemopreventive/therapeutic potential of apigenin against bladder cancer by induction of apoptosis, migration and invasion inhibition and cell cycle arrest. Akt, also known as Protein Kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration. The mechanism by which Akt protects cells from death is likely to be multifactorial, because Akt directly phosphorylates several components of the cell-death machinery . Some of the mechanisms involve the phosphorylation and inactivation of the apoptotic mediators Bad, caspase-9, FKHRL1, and IKK [17–23]. Besides, Akt is known to be a downstream of PI3K to regulate many biological processes. In our study, we confirmed that apigenin treatment in T24 cells induced apoptosis and inhibited the phosphorylation of Akt in a dose-dependent manner which meant the apigenin-treated apoptosis was involved with PI3K/Akt pathway. Notably, our data suggest that the mechanism of the tumor suppressive effect involved inhibition of PI3K/Akt signaling pathways. In this study, the reason why the PI3K/Akt expression level was markedly decreased by apigenin treatment is not clear. An earlier study on head and neck carcinomas suggests that apigenin targets EGFR, which is upstream of PI3K/Akt . In a future study, the correlation between apigenin and EGFR expression levels in bladder cancer needs to be examined.
The Bcl-2 protein family consists of both pro-apoptotic (Bax and Bad) and anti-apoptotic (Bcl-2) proteins that regulate mitochondrial outer membrane integrity, cytochrome c release, and caspase activation leading to apoptosis. Previous studies showed that with the activation of the PI3K/Akt pathway the expression of Bcl-2 family increased , and Akt inhibits apoptosis through mitochondrial pathways . Shifting the balance of Bcl-2 family members toward pro-apoptotic effects will activate caspase-3 and executes the apoptotic program . Therefore we investigated the effect of apigenin on Bcl-2 family. The present study indicates that apigenin treatment upregulates pro-apoptotic proteins Bax and Bad while downregulates anti-apoptotic proteins Bcl-2 and Bcl-xl protein. Change of the Bcl-2 family induces the release of cytochrome c from mitochondria into cytosol and cytosolic cytochrome c then binds to Apaf-1 and leads to the activation of caspase-3 and PARP . In our research, we also confirmed that apigenin activated caspase-3 and leaded to PARP cleavage. Thus our study proved apigenin treatment induces apoptosis in T24 cells via PI3K/Akt pathway and Bcl-2 family.
Cell cycle arrest and apoptosis represent two effective mechanisms involved in the induction of cell death . It is well established that loss of key cell cycle checkpoints is a hallmark of cancer cells, leading to abnormal proliferation and facilitating oncogenic transformation . Observations have shown that apigenin is a potent inhibitor of cell-cycle progression in a number of different cell lines [31, 32]. We also measured the effect of apigenin on cell cycle of T24 cells and found that apigenin leads to a G2/M phase arrest. The similar results were observed in human colon and breast carcinomas . In the present study, G2/M phase increased from 14.45% up to 37.94%, with almost 2.6 folds increasing, in a dose-dependent way, which indicated the apigenin-induced cell growth inhibition was involved with cell cycle arrest. Although Lepley DM, et al.  have proved a G1 arrest by apigenin in human diploid fibroblast, we observed G2/M arrest in apigenin-treated T24 cells. The difference between these results might be attributed to the cell types tested. Previous studies have shown that PI3K/Akt pathway could regulate expression of G2/M-related proteins to influence the progression of G2 to mitosis phase. Expression of active form of Akt led to an increase in the protein and mRNA level of Cdk1, whereas Akt dominant negative mutation inhibited cell proliferation by inducing G2/M arrest . Taken together, apigenin may inhibit cellular proliferation by inducing a cell cycle arrest at G2/M in T24 bladder cancer cells and probably via PI3K/Akt pathway.
In conclusion, our study demonstrates that apigenin can induce dose- and time-dependent cell death and apoptosis and inhibit migration and invasion ability in T24 bladder cancer cells. Apigenin leads to apoptosis via PI3K/Akt pathway, regulation of Bcl-2 family and activation of caspase-3 and PARP. Additionally, Apigenin also causes G2/M phase arrest. All these results indicate that apigenin can be used as a chemopreventive agent in bladder cancer. To the best of our knowledge, this is the first report showing the antitumor effect of apigenin in bladder cancer in vitro. However, further investigations of the mechanism of apigenin-treated cell inhibition are necessary.
Reagents and cell culture
Apigenin (≥ 99% pure) and MTT were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The annexin V-FITC apoptosis detection kit was from BD Biosciences (SanJose, CA, USA). Primary antibodies to Bcl-2, Bax, Bcl-xL, pro caspase-3, active caspase-3, GAPDH and poly(ADP-ribose) polymerase (PARP), and secondary antibodies were purchased from Santa-Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies to Akt, phosphorylated Akt, PDK, PI3K and Bad were purchased from Cell Signaling Technology (Beverly, MA). The bicinchoninic acid protein assay kit was obtained from Pierce Biotechnology (Rockford, IL).
The human bladder cancer cell line T24 was obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA) supplemented with 10% heat-inactivated FBS (JRH Biosciences, Lenexa, KS, USA), 100 U/ml penicillin, and 100 mg/L strep-tomycin. Cultures were maintained in a humidified atmosphere of 5% CO2 at 37°C.
Cell viability assay
The effect of apigenin on the viability of T24 cells was evaluated by MTT assay. Approximately 10 × 104 T24 cells were seeded on 96-well plates. After overnight incubation, the cells were treated with vehicle DMSO (1 uL/mL) and different concentrations of apigenin (0–80 μM in DMSO) for 24 hours. After incubation for the indicated time, MTT (20 μL of 5 mg/mL) was added to each well and incubated at 37°C for 4 h, after which the MTT solution in the medium was removed. To achieve solubilization of the formazan crystal formed in viable cells, 150 μL DMSO was added to each well before the absorbance at 490 nm was measured using an MRX II absorbance reader (Dynex Technologies, Chantilly, VA, USA). Results were expressed as a percentage of growth, with 100% representing control cells treated with DMSO alone.
In vitro invasion and motility assays
The invasion and motility assays were done as previously described  with some minor modifications. Cells were plated in a 6-well plate at a density of 8 × 104 cells/well. After overnight incubation, cells were treated with different concentrations of apigenin (0–20 μM in DMSO) for 24 hours and harvested. The treated and the control cells were suspended in medium at a concentration of 4 × 105 cells/mL, and 0.2 mL of each was added to the top chamber of uncoated (for motility assays) or Matrigel-coated (for invasion assays) PET membranes (24-well insert, 8-μm pore size; Millipore, Bedford, MA). Medium (0.6 mL) supplemented with 20% fetal bovine serum was added to each well of the plate to act as a chemoattractant in the lower chamber. Cells were incubated for 24 hours, and those that did not migrate through the pores were removed by scraping the upper surface of the membrane with a cotton swab. Cells that had migrated to the lower surface of the membrane were fixed for 5 min in 100% methanol and stained with 0.1% crystal violet for 2 min. These experiments were done in triplicate and performed a minimum of three times.
Cell apoptosis assay
The extent of apoptosis was evaluated by annexin V-FITC and flow cytometry. Cells were grown at a density of 1 × 106 cells in six-well culture dishes and were treated with different concentrations of apigenin (0–80 μM in DMSO) for 24 h. Following treatment, the cells were harvested, washed twice with pre-chilled PBS, and resuspended in 1× binding buffer at a concentration of 1 × 106 cells/ml. One hundred microliters of such solution was mixed with 5 μL annexin V-FITC and 5 μL propidium iodide for 15 min, and then 400 μL 1× binding buffer was added. Analysis was carried out using a FC500 flow cytometer with CXP software (Beckman Coulter, Fullerton, CA, USA) within 1 h. The percentage of apoptotic cells was assessed by CXP software.
Cell cycle assay
Cells were plated in six-well culture dishes at concentrations determined to yield 60–70% confluence within 24 h. Cells were then treated with different concentrations of apigenin (0–160 μM in DMSO). After 24 h, cells were washed twice with PBS then centrifuged. The pellet was fixed with 70% ethanol for 1 h at 4°C. The cells were washed with PBS and resuspended with propidium iodide solution (0.05 mg/mL) containing RNase, incubated at room temperature in the dark for 30 min. DNA content was then analyzed using the FC500 flow cytometer.
Western blot analysis
Cell were harvested at 24 h following apigenin treatment, washed, and lysed with lysis buffer (10 mmol/L Tris-HCl, 0.25 mol/ L sucrose, 5 mmol/L EDTA, 50 mmol/L NaCl, 30 mmol/L sodium pyrophosphate, 50 mmol/L NaF, 1 mmol/LNa3VO4, 1 mmol/L PMSF, and 2% cocktail [pH 7.5]). Protein concentration in the resulting lysate was determined using the bicinchoninic acid protein assay. Appropriate amounts of protein (20–30 μg) were separated by electrophoresis in 10–12% Tris-glycine polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were blocked then incubated overnight with the appropriate primary antibody at dilutions specified by the manufacturer. They were next washed and incubated with the corresponding HRP-conjugated secondary antibody at 1:1000 dilution in Tris-buffered saline-Tween 20 (10 mM Tris-Cl [pH 7.4], 150 mM NaCl, 0.1% Tween-20). Bound secondary antibody was detected using an enhanced chemiluminescence system (Pierce Biotechnology).
Statistical significance was compared between various treatment groups and controls using ANOVA. Data were considered statistically significant when P-values were <0.05.
We acknowledge all members of the Key Lab of Multi-Organ Transplantation of Health Ministry for their support. This work was supported by the National Key Clinical Specialty Construction Project of China, Key medical disciplines of Zhejiang province, Combination of traditional Chinese, Medicine and health development plan project of Zhejiang province (2012RCA016) and Western medicine key disciplines of Zhejiang Province (2012-XK-A23) and Medical Scientific Research Foundation of Zhejiang Province, China (2013KYB100).
- Birt DF, Mitchell D, Gold B, Pour P, Pinch HC: Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res. 1997, 17 (1A): 85-91.PubMedGoogle Scholar
- Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB, Piantelli M: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000, 87 (4): 595-600. 10.1002/1097-0215(20000815)87:4<595::AID-IJC21>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
- Wang IK, Lin-Shiau SY, Lin JK: Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer. 1999, 35 (10): 1517-1525. 10.1016/S0959-8049(99)00168-9.View ArticlePubMedGoogle Scholar
- Wang W, Heideman L, Chung CS, Pelling JC, Koehler KJ, Birt DF: Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog. 2000, 28 (2): 102-110. 10.1002/1098-2744(200006)28:2<102::AID-MC6>3.0.CO;2-2.View ArticlePubMedGoogle Scholar
- Yin F, Giuliano AE, Law RE, Van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res. 2001, 21 (1A): 413-420.PubMedGoogle Scholar
- Czeczot H, Tudek B, Kusztelak J, Szymczyk T, Dobrowolska B, Glinkowska G, Malinowski J, Strzelecka H: Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutat Res. 1990, 240 (3): 209-216. 10.1016/0165-1218(90)90060-F.View ArticlePubMedGoogle Scholar
- Jemal ABF, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.View ArticlePubMedGoogle Scholar
- Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK: Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003, 95 (17): 1276-1299. 10.1093/jnci/djg040.View ArticlePubMedGoogle Scholar
- De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van der Meijden AP, Vegt PD, Debruyne FM, Ruitenberg EJ: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother. 1992, 34 (5): 306-312. 10.1007/BF01741551.View ArticlePubMedGoogle Scholar
- Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000, 163 (4): 1124-1129. 10.1016/S0022-5347(05)67707-5.View ArticlePubMedGoogle Scholar
- Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, Li LC, Dahiya R: A component of green tea, (-)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun. 2007, 354 (4): 852-857. 10.1016/j.bbrc.2007.01.003.View ArticlePubMedGoogle Scholar
- Bai Y, Mao QQ, Qin J, Zheng XY, Wang YB, Yang K, Shen HF, Xie LP: Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci. 2010, 101 (2): 488-493. 10.1111/j.1349-7006.2009.01415.x.View ArticlePubMedGoogle Scholar
- Boatright KM, Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol. 2003, 15 (6): 725-731. 10.1016/j.ceb.2003.10.009.View ArticlePubMedGoogle Scholar
- Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene. 2003, 22 (56): 8983-8998. 10.1038/sj.onc.1207115.View ArticlePubMedGoogle Scholar
- Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000, 275 (15): 10761-10766. 10.1074/jbc.275.15.10761.View ArticlePubMedGoogle Scholar
- Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. 10.1038/nrc839.View ArticlePubMedGoogle Scholar
- Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91 (2): 231-241. 10.1016/S0092-8674(00)80405-5.View ArticlePubMedGoogle Scholar
- Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998, 282 (5392): 1318-1321.View ArticlePubMedGoogle Scholar
- Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999, 96 (6): 857-868. 10.1016/S0092-8674(00)80595-4.View ArticlePubMedGoogle Scholar
- Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401 (6748): 82-85. 10.1038/43466.View ArticlePubMedGoogle Scholar
- Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999, 401 (6748): 86-90. 10.1038/43474.View ArticlePubMedGoogle Scholar
- Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN: Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A. 1997, 94 (8): 3627-3632. 10.1073/pnas.94.8.3627.PubMed CentralView ArticlePubMedGoogle Scholar
- Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000, 404 (6779): 782-787. 10.1038/35008115.View ArticlePubMedGoogle Scholar
- Masuelli L, Marzocchella L, Quaranta A, Palumbo C, Pompa G, Izzi V, Canini A, Modesti A, Galvano F, Bei R: Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling. Front Biosci. 2011, 16: 1060-1068. 10.2741/3735.View ArticleGoogle Scholar
- Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A: Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene. 2004, 23 (34): 5781-5791. 10.1038/sj.onc.1207698.View ArticlePubMedGoogle Scholar
- Chan TO, Rittenhouse SE, Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 1999, 68: 965-1014. 10.1146/annurev.biochem.68.1.965.View ArticlePubMedGoogle Scholar
- Brown GC, Borutaite V: Nitric oxide, cytochrome c and mitochondria. Biochem Soc Symp. 1999, 66: 17-25.View ArticlePubMedGoogle Scholar
- Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997, 275 (5303): 1129-1132. 10.1126/science.275.5303.1129.View ArticlePubMedGoogle Scholar
- King KL, Cidlowski JA: Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998, 60: 601-617. 10.1146/annurev.physiol.60.1.601.View ArticlePubMedGoogle Scholar
- Pan J, She M, Xu ZX, Sun L, Yeung SC: Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res. 2005, 65 (9): 3671-3681. 10.1158/0008-5472.CAN-04-2744.View ArticlePubMedGoogle Scholar
- Lepley DM, Li B, Birt DF, Pelling JC: The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis. 1996, 17 (11): 2367-2375. 10.1093/carcin/17.11.2367.View ArticlePubMedGoogle Scholar
- Lepley DM, Pelling JC: Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinog. 1997, 19 (2): 74-82. 10.1002/(SICI)1098-2744(199707)19:2<74::AID-MC2>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Lee SRPJ, Park EK, Chung CH, Kang SS, Bang OS: Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol. 2005, 205 (2): 270-277. 10.1002/jcp.20395.View ArticlePubMedGoogle Scholar
- Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987, 47 (12): 3239-3245.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.